Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:AIM NYSEAMERICAN:PHGE NASDAQ:REVB NASDAQ:SXTP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$0.50-2.9%$0.68$0.48▼$20.35$4.09M1.243.33 million shs38,561 shsPHGEBiomX$0.65-5.1%$3.77$0.62▼$14.71$1.03M1.02835,385 shs126,817 shsREVBRevelation Biosciences$1.04-2.7%$1.22$0.99▼$40.08$3.87M-0.14491,507 shs37,457 shsSXTP60 Degrees Pharmaceuticals$1.66+0.6%$2.03$1.29▼$14.68$4.38M2.693.29 million shs19,105 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech+0.33%-0.58%-13.11%-50.76%-94.34%PHGEBiomX-13.88%-20.93%-81.42%-87.15%-93.80%REVBRevelation Biosciences-4.46%-7.76%-14.40%-32.70%-96.93%SXTP60 Degrees Pharmaceuticals-0.60%+3.12%-11.29%-62.33%-82.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$0.50-2.9%$0.68$0.48▼$20.35$4.09M1.243.33 million shs38,561 shsPHGEBiomX$0.65-5.1%$3.77$0.62▼$14.71$1.03M1.02835,385 shs126,817 shsREVBRevelation Biosciences$1.04-2.7%$1.22$0.99▼$40.08$3.87M-0.14491,507 shs37,457 shsSXTP60 Degrees Pharmaceuticals$1.66+0.6%$2.03$1.29▼$14.68$4.38M2.693.29 million shs19,105 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech+0.33%-0.58%-13.11%-50.76%-94.34%PHGEBiomX-13.88%-20.93%-81.42%-87.15%-93.80%REVBRevelation Biosciences-4.46%-7.76%-14.40%-32.70%-96.93%SXTP60 Degrees Pharmaceuticals-0.60%+3.12%-11.29%-62.33%-82.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00BuyN/AN/APHGEBiomX 2.00Hold$26.003,931.01% UpsideREVBRevelation Biosciences 1.00SellN/AN/ASXTP60 Degrees Pharmaceuticals 2.25Hold$14.10749.40% UpsideCurrent Analyst Ratings BreakdownLatest PHGE, REVB, AIM, and SXTP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/27/2026REVBRevelation Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/9/2026SXTP60 Degrees Pharmaceuticals Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$11.20 ➝ $4.203/27/2026SXTP60 Degrees Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/9/2026PHGEBiomX HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold2/6/2026AIMAIM ImmunoTech Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$90K45.46N/AN/A($2.99) per share-0.17PHGEBiomXN/AN/AN/AN/A($12.50) per shareN/AREVBRevelation BiosciencesN/AN/AN/AN/A$1.28 per shareN/ASXTP60 Degrees Pharmaceuticals$1.41M3.11N/AN/A($5.85) per share-0.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$13.96M-$24.68N/AN/AN/A-15,861.36%N/A-209.50%N/APHGEBiomX-$36.20M-$3.21N/AN/AN/AN/A-2,923.50%-83.44%5/14/2026 (Estimated)REVBRevelation Biosciences-$8.91M-$62.09N/AN/AN/AN/A-134.18%-105.47%5/7/2026 (Estimated)SXTP60 Degrees Pharmaceuticals-$7.36M-$13.88N/AN/AN/A-550.67%N/A-132.47%5/21/2026 (Estimated)Latest PHGE, REVB, AIM, and SXTP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026SXTP60 Degrees Pharmaceuticals-$0.76N/AN/AN/A$0.44 millionN/A5/7/2026N/AREVBRevelation Biosciences-$1.15N/AN/AN/AN/AN/A3/27/2026Q4 2025AIMAIM ImmunoTechN/A-$0.4480N/A-$0.4480N/A$0.02 million2/26/2026Q4 2025REVBRevelation Biosciences-$1.41-$1.65-$0.24-$1.65N/AN/A2/19/2026Q4 2025PHGEBiomXN/A$6.99N/A$6.99N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/APHGEBiomXN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/ASXTP60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTechN/A0.530.53PHGEBiomXN/A0.870.87REVBRevelation BiosciencesN/A5.415.41SXTP60 Degrees PharmaceuticalsN/A2.662.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%PHGEBiomX40.57%REVBRevelation Biosciences12.80%SXTP60 Degrees Pharmaceuticals7.96%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.04%PHGEBiomX21.80%REVBRevelation Biosciences8.04%SXTP60 Degrees Pharmaceuticals1.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech208.15 million8.15 millionNot OptionablePHGEBiomX1201.59 million1.25 millionN/AREVBRevelation Biosciences103.72 million3.42 millionNot OptionableSXTP60 Degrees Pharmaceuticals32.64 million2.59 millionNot OptionablePHGE, REVB, AIM, and SXTP HeadlinesRecent News About These CompaniesShort Interest in 60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) Rises By 13.4%May 3 at 3:29 AM | americanbankingnews.com60 Degrees Pharmaceuticals (SXTP) price target decreased by 19.89% to 14.38April 30, 2026 | msn.com60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel WebsiteApril 15, 2026 | markets.businessinsider.com60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should KnowApril 3, 2026 | zacks.comInfrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVApril 2, 2026 | freep.comFInfrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVApril 2, 2026 | freep.comF60 Degrees Pharmaceuticals Announces 2025 Annual ResultsMarch 31, 2026 | globenewswire.com60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut ExtractMarch 18, 2026 | globenewswire.com60 Degrees Pharmaceuticals Updates Opinion for ATM ProgramMarch 14, 2026 | theglobeandmail.comWhat's going on with 60 Degrees Pharmaceuticals on Friday?March 13, 2026 | msn.com60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical TrialMarch 11, 2026 | globenewswire.com60 Degrees Pharmaceuticals (SXTP) Partners With GoodRx to Expand Access to ARAKODAFebruary 24, 2026 | insidermonkey.com60 Degrees Pharmaceuticals (SXTP) price target increased by 300.00% to 17.95February 4, 2026 | msn.com60 Degrees Pharmaceuticals shares slide after unveiling GoodRx collaborationFebruary 2, 2026 | msn.com60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx PartnershipFebruary 2, 2026 | globenewswire.com60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx UseJanuary 29, 2026 | finance.yahoo.com60 Degrees Pharmaceuticals shares slide after Nasdaq flags delisting riskJanuary 26, 2026 | msn.com60 Degrees Pharmaceuticals stock tumbles after Nasdaq delisting noticeJanuary 26, 2026 | au.investing.com60 Degrees Pharmaceuticals stock soars on new telehealth partnershipJanuary 22, 2026 | za.investing.com60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria PreventionJanuary 22, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026Rocket Lab Is Back at a Line in the Sand—Now What? By Ryan Hasson | April 16, 2026This New ETF Aims to Capitalize on Surging AI Memory Chip DemandBy Jessica Mitacek | April 13, 2026Verizon Q1 Earnings Dip—A Buying Opportunity for VZ Stock?By Thomas Hughes | April 28, 20262 Crypto Stocks Flashing Bullish Signals as Bitcoin Tops $75,000By Dan Schmidt | April 21, 2026PHGE, REVB, AIM, and SXTP Company DescriptionsAIM ImmunoTech NYSEAMERICAN:AIM$0.50 -0.02 (-2.90%) As of 10:56 AM Eastern This is a fair market value price provided by Massive. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.BiomX NYSEAMERICAN:PHGE$0.64 -0.04 (-5.15%) As of 10:33 AM EasternBiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.Revelation Biosciences NASDAQ:REVB$1.04 -0.03 (-2.71%) As of 10:58 AM Eastern This is a fair market value price provided by Massive. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.60 Degrees Pharmaceuticals NASDAQ:SXTP$1.66 +0.01 (+0.61%) As of 10:56 AM Eastern This is a fair market value price provided by Massive. Learn more.60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
